Drug intelligence / Profile preview

IMD-2101

Development stage: Unknown
Lead developer: Affinity Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IMD-2101 is a tumor-microenvironment-activated antibody-drug conjugate (ADC) targeting Human Epidermal Growth Factor Receptor 2 (HER2), developed by Affinity Biopharmaceutical. The therapeutic is designed to deliver a cytotoxic payload specifically to HER2-expressing tumor cells. By utilizing a linker that is selectively cleaved within the tumor microenvironment, IMD-2101 aims to enhance the therapeutic index by reducing systemic exposure to the toxin and minimizing off-target effects. It is currently in Phase 1 development for the treatment of various advanced solid tumors.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on IMD-2101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMD-2101.

Explore the full profile